Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
2.580
-0.060 (-2.27%)
At close: Aug 28, 2026, 4:00 PM EDT
2.680
+0.100 (3.88%)
After-hours: Aug 28, 2026, 7:52 PM EDT
Atossa Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
16
Market Cap
25.75M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
ATOS News
- 22 days ago - Atossa Therapeutics reports Q2 EPS (95c) vs. (98c) last year - TheFly
- 22 days ago - Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update - PRNewsWire
- 22 days ago - Atossa Therapeutics Quarterly report: Q2 2026 - Filings
- 22 days ago - Atossa Therapeutics Earnings release: Q2 2026 - Filings
- 4 weeks ago - Atossa Therapeutics sees opportunities for (Z)-endoxifen beyond breast cancer - TheFly
- 4 weeks ago - Meet Atossa Therapeutics: Fly Exclusive with CFO Mark Daniel - TheFly
- 4 weeks ago - Atossa Therapeutics’ (Z)-endoxifen compounds show anti-breast cancer action - TheFly
- 4 weeks ago - Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer - PRNewsWire